Oncodesign Precision Medicine Announces a 6 Million Euros Bank Financing from Caisse d’Épargne Bourgogne Franche Comté, Crédit Agricole de Champagne Bourgogne and Société Générale
2023年10月6日 - 1:00AM
ビジネスワイヤ（英語）
- This non-dilutive financing enables OPM to continue the
clinical development of OPM-101 and to support the development of
its products portfolio and technologies
- This unique and strategic agreement highlights :
- the strength of
OPM's regional funding and geographical roots
- the ecosystem's
confidence in OPM’s project
- This financing strengthens OPM’s financial visibility with a
cash position of €13.35 M at 03/10/2023, ensuring the development
of our programs
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ;
Mnemonic : ALOPM), a biopharmaceutical company specializing in
precision medicine for the treatment of resistant and metastatic
cancer, announces the successful signing of a financing agreement
of €6 M granted by three regional banks: Caisse d'Épargne Bourgogne
Franche Comté, Crédit Agricole Champagne Bourgogne and Société
Générale. This financing is guaranteed by Bpifrance and P.C.G.
Oncodesign Precision Medicine, listed on Euronext Growth since
November 2022, and having completed an €8 M capital increase in
December 2022, of which €5 M were provided by the three
co-founders, has signed a financing agreement with three regional
banks. It highlights the trust, developed over time, of the OPM
regional ecosystem and the key role played by geographical roots in
the development of technology companies.
Over the past year, many milestones have been achieved:
- two OPM molecules have entered Phase I clinical trial in
healthy volunteers: OPM-201, licensed to Servier, for Parkinson's
disease, and OPM-101 for inflammatory bowel disease,
- the StarT Pancreas partnership with Servier has been launched,
highlighting OPM's expertise in AI assisted identification and
validation of biological targets,
- two industrial programs (Promethe for Molecular Radio Therapy,
and FederAidd for the use of AI to reduce the development time of
therapeutic molecules) have been launched.
This €6 M loan is equally provided by the three regional banks:
Caisse d'Épargne Bourgogne Franche Comté, Crédit Agricole de
Champagne Bourgogne, and Société Générale, and is guaranteed by
Bpifrance and P.C.G.
This financing increases OPM's cash position to €13.35 M on
03/10/2023. It enables OPM to progress as planned in the clinical
development of OPM-101, specifically by continuing the MAD part of
the ongoing Phase I trial in healthy volunteers and preparing Phase
IIa, while continuing to develop the companies’ technologies and
product portfolio.
It enables the management and the team to focus on the company's
mission, which is the development of treatments for resistant and
metastatic cancers, and to continue creating value within the
company.
Philippe GENNE, President and Chief Executive Officer of
Oncodesign Precision Medicine, said: “In a difficult general
economic context for biotechs, this agreement is a real expression
of faith from our loyal regional banking partners, with whom we've
been working for more than 20 years. After the success of
Oncodesign SA, they are following us in OPM's adventure through
this innovative agreement for this sector, which goes beyond their
traditional fields of activity. In particular, this financing will
enable us to confidently continue the development of OPM-101
towards Phase II, without any potential time-loss due to the
prevailing stock market gloom. We appreciate this expression of
confidence from our regional ecosystem, which demonstrates its
strong conviction and commitment to OPM's value-creation
project.”
Karine Lignel, COO of Oncodesign Precision Medicine,
added: “Over time, we have developed a relationship of trust with
our shareholders, who supported us during OPM's last capital
increase, and with regional banking institutions, which have
recognized the value of our projects, even though this is not a
traditional financing for them. This proves, if proof were needed,
that trust is developed over time and is strengthened by successful
projects such as last year's sale of Oncodesign Services and the
creation of OPM. Our cash visibility has therefore improved, and we
are working to complete this bank financing through government
funding.”
David Sarret, Head of Healthcare Experts Division of Caisse
d'Epargne Bourgogne Franche-Comté, concluded: “As a funder of
the healthcare sector and innovative companies, the Caisse
d'Epargne Bourgogne Franche-Comté is proud to contribute to the
financing of research & development activities of Dijon-based
biotech Oncodesign Precision Medicine by playing the role of
arranger and agent during the transaction. This personalized
financing, structured in close collaboration with Oncodesign
Precision Medicine's management team, is entirely in phase with our
commitment to support healthcare actors in their value-creation
projects over the long term.”
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), the result of the transfer
of Oncodesign's Biotech and AI activities, is a biopharmaceutical
company specializing in precision medicine to treat resistant and
metastatic cancers.
OPM's innovative technologies are (i) OncoSNIPER for the
selection of therapeutic targets using artificial intelligence;
(ii) Nanocyclix® for the design and selection of macrocyclic small
molecule kinase inhibitors and (iii) Promethe for the design and
selection of radiolabeled biological molecules for systemic
radiotherapy.
From these technologies, OPM has built a portfolio of
therapeutic products. A first drug candidate based on the
Nanocyclix® technology entered the clinical phase in 2022, in
partnership with SERVIER (which exercised its option for an
exclusive worldwide license on the program) to treat Parkinson's
disease. OPM-101 is OPM's second candidate to enter the clinic, in
the treatment of chronic immuno-inflammatory diseases. Finally, OPM
is also collaborating with Servier to discover new therapeutic
targets for the treatment of pancreatic adenocarcinoma based on its
OncoSNIPER technology. In addition, OPM is seeking a partner for
Florepizol, a radiotracer specific for the mutated EGFR target,
which has successfully completed Phase I. Finally, OPM has a
significant portfolio of early-stage projects with Nanocyclix® and
Promethe in oncology. With this portfolio of molecules and
diversified therapeutic targets, OPM's mission is to discover
effective therapies to treat resistant and advanced cancers. Based
in Dijon, at the heart of the university and hospital cluster, OPM
has 25 employees.
More info at: oncodesign.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231005370180/en/
OPM Karine Lignel Deputy General Manager Tel: +33 (0)3 80
78 41 93 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel: +33 (0)1 44 71
00 15 oncodesign@newcap.eu
Oncodesign Precision Med... (EU:ALOPM)
過去 株価チャート
から 4 2024 まで 5 2024
Oncodesign Precision Med... (EU:ALOPM)
過去 株価チャート
から 5 2023 まで 5 2024
